Pfizer PFE expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) of several of its key ...

Aktis Oncology filed for an initial public offering in the United States on Friday, as stock market listings from the biotech ...

Cencora announced Monday that it has entered a definitive agreement to speed up its buyout of specialty practice network OneOncology, which values the latter at an enterprise valuation of $7.4 bill | ...

CG Oncology leads in NMIBC treatment with creto, strong efficacy data, and $2B+ revenue potential. Learn more about CGON ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued ...

Power partnership oncology at MD Anderson expands access to expert cancer care, research, and clinical trials across seven U.S. health systems.

Coherus Oncology, Inc. is rated a Buy driven by a promising clinical pipeline and undervaluation. Learn more about CHRS stock ...

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...

Integrative oncology combines standard cancer treatments with complementary therapies to manage symptoms and improve ...

Pamela Jones, DVM, DACVIM (Oncology), explains why lymphoma isn’t one disease and how phenotyping, client goals, and teamwork ...

New York City-based New York-Presbyterian Hudson Valley Hospital will pay $6.8 million to resolve allegations it improperly paid a Westchester, N.Y.-based oncology practice to induce referrals later ...